Overview on Molecular Markers to Implement Cervical Cancer Prevention: Challenges and Perspectives

HPV Model: From Gender Medicine to Healthcare of the Couple

“…We decided to test HC2 performances in male population, since this method is widely used in women, particularly in the triage of cervical cytological abnormalities, in post-treatment follow-up and in primary screening [14]. GP5+/6+-based PCR are actually considered the most sensitive tool to detect HPV infection [14].…”

“…Whether the same preventive tools may be used for both men and women, why we should not use on men the same validated diagnostic tools which are currently used on women, optimizing them according to gender? In female population, FDA-approved liquid-based cytology (LBC) is widely used to detect cervical abnormalities and, together with HPV-DNA test, has proven to be effective in reducing the burden of cervical cancer disease [14]. Moreover, E6/E7 mRNA testing, with its high level of specificity, is able to prevent overtreatment by stratifying the risk [14].…”

“…In female population, FDA-approved liquid-based cytology (LBC) is widely used to detect cervical abnormalities and, together with HPV-DNA test, has proven to be effective in reducing the burden of cervical cancer disease [14]. Moreover, E6/E7 mRNA testing, with its high level of specificity, is able to prevent overtreatment by stratifying the risk [14]. Routine screening of sexually active males is hampered by the lack of a simple, convenient and effective screening technique.…”